Cholera Vaccine Market by Product (Dukoral, Shanchol, Vaxchora, Euvichol & Euvichol-Plus, and others) and End User (Hospitals & Clinics, Research & Academic Laboratories, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025
- ALL2954259
- 149 Pages
- March 2019
- Pharmaceuticals
Cholera Vaccine Market Overview:
The global cholera vaccine market generated $65 million in 2017, and is projected to reach $207 million by 2025, growing at a CAGR of 15.6% from 2018 to 2025.
Cholera is an acute intestinal infection that causes rapidly dehydrating diarrheal disease, which is caused by toxigenic serogroups of the bacterium Vibrio cholera. The disease is closely associated with poverty, poor sanitation, and lack of clean drinking water. Historically, devastating outbreaks of cholera resulted in millions of cases and hundreds of thousands of deaths. Currently, cholera remains an important public health problem in many countries, occurring as an endemic disease in some regions and causing major epidemics in some low- and middle-income countries (LMICs). The vaccine is used to control cholera and is mainly recommended for travelers and the people living in cholera-affected region.
There is an increase in the demand for cholera vaccine due to lack of proper sanitation & consumption of contaminated food and growth in the awareness about cholera preventive care. In addition, development of novel approaches for new cholera vaccine further drive the market growth. However, risk of adverse effects and the time taken for the regulatory approval is projected to impede the market growth. On the contrary, high growth opportunities in untapped markets are expected to offer significant profitable opportunities for the market players.
The global cholera vaccine market is segmented based on product, end user, and region. Based on product, the market is segmented into Dukoral, Shanchol, Vaxchora, Euvichol & Euvichol-Plus, and others. Depending on end user, the market is categorized into hospitals & clinics, research & academic laboratories, and others. Based on region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits For Cholera Vaccine Market:
- This report provides a detailed quantitative analysis of the current market trends and future estimations from 2018 to 2025, which assists to identify the prevailing market opportunities.
- An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
- A comprehensive analysis of the factors that drive and restrain the growth of the global cholera vaccine market is provided.
- An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
Cholera Vaccine Key Market Segments:
By Product
- Dukoral
- Shanchol
- Vaxchora
- Euvichol & Euvichol-Plus
- Others
By End User
- Hospitals & Clinics
- Research & Academic Laboratories
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Sweden
- Rest of Europe
- Asia-Pacific
- Australia
- Japan
- India
- Vietnam
- Rest of Asia-Pacific
- LAMEA
- Nigeria
- Malawi
- Zambia
- Rest of LAMEA
Key Market Players
- Valneva SE
- Emergent BioSolutions, Inc. (PaxVax, Inc.)
- Astellas Pharma, Inc.
- Sanofi (Shantha Biotechnics Private Limited)
- Eubiologics Co., Ltd.
- Johnson & Johnson (Crucell)
- Celldex Therapeutics, Inc.
- The other players in the value chain include (profiles not included in the report):
- Merck & Co., Inc.
- GlaxoSmithKline plc.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Top Player Positioning, 2017
3.4. Porters five forces analysis
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Lack of proper sanitation and consumption of contaminated food
3.5.1.2. Rise in awareness about cholera preventive care
3.5.1.3. Development of novel approaches for new cholera vaccine
3.5.2. Restraints
3.5.2.1. Risk of adverse effects
3.5.2.2. The time taken for the regulatory approval
3.5.3. Opportunities
3.5.3.1. High growth opportunities in untapped markets
CHAPTER 4: CHOLERA VACCINE MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Dukoral
4.2.1. Key market trends and growth opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Shanchol
4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Vaxchora
4.4.1. Key market trends and growth opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Euvichol & Euvichol-Plus
4.5.1. Key market trends and growth opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Others
4.6.1. Key market trends and growth opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
CHAPTER 5: CHOLERA VACCINE MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospitals & Clinics
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Research & Academic Laboratories
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Others
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
CHAPTER 6: CHOLERA VACCINE MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. North America cholera vaccine market, by country
6.2.2.1. U.S. cholera vaccine market by product
6.2.2.2. U.S. cholera vaccine market by end user
6.2.2.3. Canada cholera vaccine market by product
6.2.2.4. Canada cholera vaccine market by end user
6.2.2.5. Mexico cholera vaccine market by product
6.2.2.6. Mexico cholera vaccine market by end user
6.2.3. North America cholera vaccine market, by product
6.2.4. North America cholera vaccine market, by end user
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Europe cholera vaccine market, by country
6.3.2.1. Germany cholera vaccine market by product
6.3.2.2. Germany cholera vaccine market by end user
6.3.2.3. France cholera vaccine market by product
6.3.2.4. France cholera vaccine market by end user
6.3.2.5. UK cholera vaccine market by product
6.3.2.6. UK cholera vaccine market by end user
6.3.2.7. Italy cholera vaccine market by product
6.3.2.8. Italy cholera vaccine market by end user
6.3.2.9. Sweden cholera vaccine market by product
6.3.2.10. Sweden cholera vaccine market by end user
6.3.2.11. Rest of Europe cholera vaccine market by product
6.3.2.12. Rest of Europe cholera vaccine market by end user
6.3.3. Europe cholera vaccine market, by product
6.3.4. Europe cholera vaccine market, by end user
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Asia-Pacific cholera vaccine market, by country
6.4.2.1. Australia cholera vaccine market by product
6.4.2.2. Australia cholera vaccine market by end user
6.4.2.3. Japan cholera vaccine market by product
6.4.2.4. Japan cholera vaccine market by end user
6.4.2.5. India cholera vaccine market by product
6.4.2.6. India cholera vaccine market by end user
6.4.2.7. Vietnam cholera vaccine market by product
6.4.2.8. Vietnam cholera vaccine market by end user
6.4.2.9. Rest of Asia-Pacific cholera vaccine market by product
6.4.2.10. Rest of Asia-Pacific cholera vaccine market by end user
6.4.3. Asia-Pacific cholera vaccine market, by product
6.4.4. Asia-Pacific cholera vaccine market, by end user
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. LAMEA cholera vaccine market, by country
6.5.2.1. Nigeria cholera vaccine market by product
6.5.2.2. Nigeria cholera vaccine market by end user
6.5.2.3. Malawi cholera vaccine market by product
6.5.2.4. Malawi cholera vaccine market by end user
6.5.2.5. Zambia cholera vaccine market by product
6.5.2.6. Zambia cholera vaccine market by end user
6.5.2.7. Rest of LAMEA cholera vaccine market by product
6.5.2.8. Rest of LAMEA cholera vaccine market by end user
6.5.3. LAMEA cholera vaccine market, by product
6.5.4. LAMEA cholera vaccine market, by end user
CHAPTER 7: COMPANY PROFILES
7.1. Astellas Pharma, Inc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Business performance
7.2. Celldex Therapeutics, Inc.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Business performance
7.2.4. Key strategic moves and developments
7.3. Emergent BioSolutions, Inc. (PaxVax, Inc.)
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Business performance
7.4. Eubiologics Co., Ltd.
7.4.1. Company overview
7.4.2. Company snapshot
7.5. Johnson & Johnson (Crucell)
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance
7.6. Sanofi (Shantha Biotechnics Private Limited)
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Business performance
LIST OF TABLES
TABLE 01. GLOBAL CHOLERA VACCINE MARKET, BY PRODUCT, 20172025 ($MILLION)
TABLE 02. CHOLERA VACCINE MARKET FOR DUKORAL, BY REGION, 20172025 ($MILLION)
TABLE 03. CHOLERA VACCINE MARKET FOR SHANCHOL, BY REGION, 20172025 ($MILLION)
TABLE 04. CHOLERA VACCINE MARKET FOR VAXCHORA, BY REGION, 20172025 ($MILLION)
TABLE 05. CHOLERA VACCINE MARKET FOR EUVICHOL AND EUVICHOL-PLUS BY REGION, 20172025 ($MILLION)
TABLE 06. CHOLERA VACCINE MARKET FOR OTHER PRODUCTES BY REGION, 20172025 ($MILLION)
TABLE 07. GLOBAL CHOLERA VACCINE MARKET, BY END USER, 20172025 ($MILLION)
TABLE 08. CHOLERA VACCINE MARKET FOR HOSPITALS & CLINICS, BY REGION, 20172025 ($MILLION)
TABLE 09. CHOLERA VACCINE MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 20172025 ($MILLION)
TABLE 10. CHOLERA VACCINE MARKET FOR OTHER END USERS, BY REGION, 20172025 ($MILLION)
TABLE 11. GLOBAL CHOLERA VACCINE MARKET REVENUE, BY REGION, 20172025 ($MILLION)
TABLE 12. NORTH AMERICA CHOLERA VACCINE MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 13. U.S. CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 14. U.S. CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 15. CANADA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 16. CANADA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 17. MEXICO CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 18. MEXICO CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 19. NORTH AMERICA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 20. NORTH AMERICA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 21. EUROPE CHOLERA VACCINE MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 22. GERMANY CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 23. GERMANY CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 24. FRANCE CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 25. FRANCE CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 26. UK CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 27. UK CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 28. ITALY CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 29. ITALY CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 30. SWEDEN CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 31. SWEDEN CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 32. REST OF EUROPE CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 33. REST OF EUROPE CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 34. EUROPE CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 35. EUROPE CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 36. ASIA-PACIFIC CHOLERA VACCINE MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 37. AUSTRALIA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 38. AUSTRALIA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 39. JAPAN CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 40. JAPAN CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 41. INDIA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 42. INDIA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 43. VIETNAM CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 44. VIETNAM CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 45. REST OF ASIA-PACIFIC CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 46. REST OF ASIA-PACIFIC CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 47. ASIA-PACIFIC CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 48. ASIA-PACIFIC CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 49. LAMEA CHOLERA VACCINE MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 50. NIGERIA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 51. NIGERIA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 52. MALAWI CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 53. MALAWI CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 54. ZAMBIA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 55. ZAMBIA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 56. REST OF LAMEA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 57. REST OF LAMEA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 58. LAMEA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 59. LAMEA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 60. ASTELLAS PHARMA: COMPANY SNAPSHOT
TABLE 61. CELLDEX: COMPANY SNAPSHOT
TABLE 62. EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT
TABLE 63. EMERGENT BIOSOLUTIONS: OPERATING SEGMENTS
TABLE 64. EUBIOLOGICS: COMPANY SNAPSHOT
TABLE 65. J&J: COMPANY SNAPSHOT
TABLE 66. J&J: OPERATING SEGMENTS
TABLE 67. SANOFI: COMPANY SNAPSHOT
TABLE 68. SANOFI: OPERATING SEGMENTS
LIST OF FIGURES
FIGURE 01. CHOLERA VACCINE MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS IN THE GLOBAL CHOLERA VACCINE MARKET
FIGURE 03. GLOBAL POWERED SURGICAL INSTRUMENT TOP PLAYER POSITIONING, 2017
FIGURE 04. MODERATE BARGAINING POWER OF BUYERS
FIGURE 05. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 06. LOW THREAT OF NEW ENTRANTS
FIGURE 07. MODERATE THREAT OF SUBSTITUTION
FIGURE 08. HIGH COMPETITIVE RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS, AND OPPORTUNITIES: GLOBAL CHOLERA VACCINE MARKET
FIGURE 10. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR DUKORAL, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR SHANCHOL, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR VAXCHORA, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR EUVICHOL AND EUVICHOL-PLUS, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR OTHER PRODUCTES, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR OTHER END USERS, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 18. ASTELLAS PHARMA: NET SALES, 20162018 ($MILLION)
FIGURE 19. ASTELLAS PHARMA: REVENUE SHARE BY PRODUCT SEGMENT, 2018 (%)
FIGURE 20. ASTELLAS PHARMA: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 21. CELLDEX: NET SALES, 20152017 ($MILLION)
FIGURE 22. EMERGENT BIOSOLUTIONS: NET SALES, 20152017 ($MILLION)
FIGURE 23. EMERGENT BIOSOLUTIONS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 24. J&J: NET SALES, 20152017 ($MILLION)
FIGURE 25. J&J: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 26. J&J: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 27. SANOFI: NET SALES, 20152017 ($MILLION)
FIGURE 28. SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 29. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
Similar Reports
Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...
- Publish Date: November 14, 2017
- $5370
Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...
- Publish Date: July 20, 2017
- $5370
The pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs. The global orphan drugs market accounted for $106 billion in 2015, and is anticipated to reach $169 billio...
- Publish Date: April 24, 2017
- $5370
